Literature DB >> 11548166

MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging.

M Furukawa1, S Terae, B C Chu, K Kaneko, H Kamada, K Miyasaka.   

Abstract

We assessed the utility of fluid-attenuated inversion-recovery (FLAIR) and diffusion-weighted (DWI) images in investigation of tacrolimus (FK-506) encephalopathy, and to see whether we could predict its cause from clinical and imaging data. In seven patients with presumed FK-506 toxicity the areas involved on MRI were similar to those in cyclosporin A (CsA) toxicity. The abnormal signal was most evident on FLAIR in all cases. In three of four patients who underwent DWI, no diffusion abnormalities were detected; in the remaining patient, increased diffusion was seen in the deep white matter bilaterally on the apparent diffusion coefficient map, consistent with the findings on T2-weighted spin-echo and FLAIR images. Five of the six patients for whom we had clinical data showed sudden changes in electrolyte or fluid equilibrium due to diarrhoea, a polyuria or oliguria one day before or on the day of onset of the central nervous system disturbances. We speculate that FK-506 encephalopathy is triggered by the disturbance of the electrolyte and/or fluid equilibrium, given a certain serum level of FK-506.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11548166     DOI: 10.1007/s002340100545

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  14 in total

1.  Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma.

Authors:  Mithri R Junna; Alejandro A Rabinstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12       Impact factor: 10.154

Review 2.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

3.  Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children.

Authors:  Takahisa Kanekiyo; Junichi Hara; Yoshiko Matsuda-Hashii; Hiroyuki Fujisaki; Sadao Tokimasa; Akihisa Sawada; Keiko Kubota; Kuriko Shimono; Katsumi Imai; Keiichi Ozono
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

4.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

5.  Pearls & Oy-sters: Tacrolimus neurotoxicity presenting as an isolated brainstem lesion.

Authors:  Altaf Saadi; Jeremy D Schmahmann
Journal:  Neurology       Date:  2016-03-15       Impact factor: 9.910

6.  Brain MR imaging abnormalities in kidney transplant recipients.

Authors:  Nada Besenski; Zoran Rumboldt; Osemwegie Emovon; Joyce Nicholas; Sunil Kini; Jovan Milutinovic; Milos N Budisavljevic
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

7.  Quantitative evaluation of diffusion-weighted magnetic resonance imaging of focal hepatic lesions.

Authors:  Xi-Jie Sun; Xian-Yue Quan; Fan-Heng Huang; Yi-Kai Xu
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

Review 8.  Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation.

Authors:  Andrés Server; Nuria Bargalló; Yngvar Fløisand; Jon Sponheim; Francesc Graus; John K Hald
Journal:  Neuroradiology       Date:  2017-03-02       Impact factor: 2.804

Review 9.  Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients.

Authors:  Eileen M Le; Monica E Loghin
Journal:  Curr Oncol Rep       Date:  2014-05       Impact factor: 5.075

10.  Pulsatile tinnitus as the presenting symptom in a patient with posterior reversible encephalopathy syndrome.

Authors:  Hassan Mohammed; Mayen Briggs; John Phillips
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.